In Synergy: Optimizing CAR T Development and Personalizing Patient Care Using Single-Cell Technologies
Cancer Discovery · 2023
DOI: 10.1158/2159-8290.cd-23-0010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Discovery, 2023. Verfasst von Oren Barboy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 88 Literaturangaben. Gefördert von: Howard Hughes Medical Institute, HORIZON EUROPE European Research Council, Melanoma Research Alliance.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T therapies hold immense promise to revolutionize cancer treatment. Nevertheless, key challenges, primarily in solid tumor settings, continue to hinder the application of this technology. Understanding CAR T-cell mechanism of action, in vivo activity, and clinical implications is essential for harnessing its full therapeutic potential. Single-cell genomics and cell engineering tools are becoming increasingly effective for the comprehensive research of complex biological systems. The convergence of these two technologies can accelerate CAR T-cell development. Here, we examine the potential of applying single-cell multiomics for the development of next-generation CAR T-cell therapies. Significance: Although CAR T-cell therapies have demonstrated remarkable clinical results in treating cancer, their effectiveness in most patients and tumor types remains limited. Single-cell technologies, which are transforming our understanding of molecular biology, provide new opportunities to overcome the challenges of CAR T-cell therapies. Given the potential of CAR T-cell therapy to tip the balance in the fight against cancer, it is important to understand how single-cell multiomic approaches can be leveraged to develop the next generations of more effective and less toxic CAR T-cell products and to provide powerful decision-making tools for clinicians to optimize treatment and improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
ORCID-Profile: Oren Barboy, Yonatan Katzenelenbogen, Rotem Shalita, Ido Amit
Förderung
- Howard Hughes Medical Institute
- HORIZON EUROPE European Research Council
- Melanoma Research Alliance
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Barboy, O., Katzenelenbogen, Y., Shalita, R., & Amit, I. (2023). In Synergy: Optimizing CAR T Development and Personalizing Patient Care Using Single-Cell Technologies. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-23-0010
Vancouver
Barboy O, Katzenelenbogen Y, Shalita R, Amit I. In Synergy: Optimizing CAR T Development and Personalizing Patient Care Using Single-Cell Technologies. Cancer Discovery. 2023. doi:10.1158/2159-8290.cd-23-0010
BibTeX
@article{Barboy2023,
author = {Barboy, Oren and Katzenelenbogen, Yonatan and Shalita, Rotem and Amit, Ido},
title = {In Synergy: Optimizing CAR T Development and Personalizing Patient Care Using Single-Cell Technologies},
journal = {Cancer Discovery},
year = {2023},
doi = {10.1158/2159-8290.cd-23-0010}
}
EUVIMED